Redhill Biopharma Ltd (RDHL.OQ)
RDHL.OQ on NASDAQ Stock Exchange Capital Market
Change (% chg)
Revenue & Earnings Per Share
Consensus Estimates Analysis
No consensus analysis data available.
Performance for Redhill Biopharma Ltd
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share
- BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial
- BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia
- BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg
- BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.